Research programme: pain therapeutics - ImmuPharma

Drug Profile

Research programme: pain therapeutics - ImmuPharma

Alternative Names: IPP-102199

Latest Information Update: 12 Jun 2014

Price : $50

At a glance

  • Originator ImmuPharma
  • Class Opioid peptides
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer pain; Pain; Postoperative pain

Most Recent Events

  • 12 Jun 2014 ImmuPharma is conducting preclinical development of IPP 102199 for the treatment of severe pain
  • 05 Apr 2011 Preclinical development is ongoing in France
  • 01 Feb 2008 Preclinical trials in Pain in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top